Pramipexole-Teva tablets 1 mg, 30 pcs. (Pramypeksol)
Special Price
$32.30
Regular Price
$38.00
In stock
SKU
newyork471610
release form
tablets Buy Pramipexole-Teva tablets 1 mg, 30 pcs. (Pramypeksol) in newyork free shipping. Fast international shipping USA, AU, EU, UK and others.
tablets Buy Pramipexole-Teva tablets 1 mg, 30 pcs. (Pramypeksol) in newyork free shipping. Fast international shipping USA, AU, EU, UK and others.
release form
tablets
Packing
30 pcs.
Pharmacological action
Pramipexole-Teva - dopaminergic, antiparkinsonian.
Pharmacodynamics
Pramipexole is a dopamine receptor agonist, with high selectivity and specificity binds to dopamine D2 receptors, has a pronounced affinity for dopamine D3 receptors.
Reduces motor activity deficiency in Parkinson's disease by stimulating dopamine receptors in the striatum.
Pramipexole inhibits dopamine synthesis, release and metabolism, protects dopaminergic neurons from degeneration that occurs in response to ischemia or methamphetamine neurotoxicity.
Clinical studies have shown the efficacy of pramipexole therapy in the late stages of Parkinson's disease, in which there has been a significant decrease in the number of motor disorders and a much later development of complications compared with levodopa monotherapy.
Pharmacokinetics
Absorption. Pramipexole after oral administration is rapidly and completely absorbed, reaching Cmax in plasma after about 1-3 hours. The absolute bioavailability of pramipexole exceeds 90%. The rate of absorption decreases with food intake, however, the total intake is not affected by food intake. Pramipexole is characterized by linear kinetics and a relatively small concentration variability between individual patients.
distribution. Vd is 400 liters. Plasma protein binding is less than 20%.
Metabolism and excretion. Slightly metabolized in the body. About 90% of the dose is excreted by the kidneys (80% - unchanged) and less than 2% - with feces. The total clearance of pramipexole is about 500 ml / min, renal clearance is about 400 ml / min.
The final T1 / 2 is 8 hours in young healthy volunteers and about 12 hours in older people.
Indications for treatment of the disease when the disease is weak or not associated with a combination of the following: or become unstable and fluctuations in the therapeutic effect occur (on-off).
Contraindications
hypersensitivity to pramipexole or any of the components of the drug
breastfeeding
age up to 18 years.
Precautions: renal failure, arterial hypotension, cardiovascular disease, simultaneous use with dopamine receptor agonists, sedatives, cimetidine, amantadine, ethanol pregnancy.
Composition
Active ingredient: pramipexole dihydrochloride monohydrate 1 mg
Excipients: mannitol MCC carboxymethyl starch sodium povidone K25 silicon dioxide colloidal magnesium sodium stearate stearyl fumarate
Dosage and administration
Inside, regardless of food intake, with plenty of fluids.
The daily dose should be evenly divided into 3 doses.
The initial daily dose of 264 micrograms of pramipexole base (375 micrograms of pramipexole dihydrochloride) should be increased every 5–7 days.
Side effects
From the nervous system: often - confusion, insomnia, dizziness, impaired consciousness, depression, anxiety infrequently - extrapyramidal syndrome, amnesia, hypesthesia, dystonia, myoclonus, tremor, ataxia, hypokinesia, delirium, suicidal mood rarely - malignant antipsychotic syndrome (hyperthermia, muscle rigidity, akathisia, autonomic lability, impaired thinking).
From the musculoskeletal system: rarely - muscle hypertonicity, leg muscle cramps, muscle twitching, arthritis, bursitis, myasthenia gravis, pain in the lumbosacral spine, chest pain, neck pain.
From the digestive system: often - loss of appetite, dysphagia, dyspepsia, abdominal pain, flatulence, diarrhea, dry mouth, vomiting.
From the respiratory system: infrequently - pharyngitis, sinusitis, rhinitis, dyspnea, increased cough, voice change is very rare - flu-like syndrome, pulmonary infiltration, pleural effusion.
From the genitourinary system: rarely - urinary tract infection, increased urination.
From the CCC side: often - orthostatic hypotension infrequently - tachycardia, increased CPK activity, angina pectoris, arrhythmias. In some patients, a decrease in blood pressure may occur at the beginning of treatment, especially if the dose is increased too quickly.
On the part of the sensory organs: often - conjunctivitis, accommodation paralysis, diplopia, cataracts, increased IOP, hearing loss.
Other: often - allergic reactions, fever, weight loss, sweating rarely - retroperitoneal fibrosis. Cases of development of peripheral edema were noted.
Drug interaction
Pramipexole binds to a small extent (less than 20%) with plasma proteins and undergoes biotransformation. Therefore, interactions with other drugs that affect plasma protein binding or excretion due to biotransformation are unlikely.
Selegiline and levodopa do not affect the pharmacokinetics of pramipexole. Pramipexole increases Cmax of levodopa by 40% and reduces Tmax from 2.5 to 0.5 hours.
Drugs that inhibit the active secretion of cationic drugs through the renal tubules (for example, cimetidine), or which themselves are eliminated by active secretion through the renal tubules, interact with pramipexole, which is expressed in a decrease in clearance of one or both drugs. In the case of the simultaneous use of amantadine and pramipexole, it is necessary to pay attention to such signs of dopamine excessive stimulation as dyskinesia, agitation or hallucinations. In such cases, it is necessary to reduce the dose.
Diltiazem, triamteren, verapamil, quinidine, quinine reduce the clearance of pramipexole by 20%.
Interaction with anticholinergic drugs and amantadine has not been studied. However, interaction with amantadine is possible, because drugs have a similar excretion mechanism. Anticholinergic drugs are mainly excreted by the metabolic route, so interaction with pramipexole is unlikely.
With an increase in the dose of pramipexole, a reduction in the dose of levodopa is recommended, while it is necessary to maintain the concentration of other antiparkinsonian drugs at a constant level.
Dopamine receptor agonists (derivatives of phenothiazine, butyrophenone, thioxanthene, metoclopramide) reduce the effectiveness of pramipexole.
Because of the possible cumulative effects, patients should be advised to be careful while using sedative drugs or ethanol (alcohol) and pramipexole, as well as taking medications that increase the concentration of pramipexole in the plasma (for example, cimetidine).
Overdose of
Symptoms: nausea, vomiting, hyperkinesia, hallucinations, agitation and decreased blood pressure.
Treatment: gastric lavage, symptomatic therapy. There is no specific antidote. The effectiveness of hemodialysis has not been established.
Storage conditions
In the dark place at a temperature of no higher than 25 ° C.
Term hodnosty
2 years
Deystvuyuschee substances
Pramypeksol
Pharmacy terms
Prescription
Form of Treatment
tablets
Pramipexole-Teva tablets 1 mg, 30 pcs. (Pramypeksol) newyork in pharmacy online. Cheap price, instruction, side effects, dosage. Pramipexole-Teva tablets 1 mg, 30 pcs. - Sale. PayPal accept. Free shipping newyork. Fast international shipping.
tablets
Packing
30 pcs.
Pharmacological action
Pramipexole-Teva - dopaminergic, antiparkinsonian.
Pharmacodynamics
Pramipexole is a dopamine receptor agonist, with high selectivity and specificity binds to dopamine D2 receptors, has a pronounced affinity for dopamine D3 receptors.
Reduces motor activity deficiency in Parkinson's disease by stimulating dopamine receptors in the striatum.
Pramipexole inhibits dopamine synthesis, release and metabolism, protects dopaminergic neurons from degeneration that occurs in response to ischemia or methamphetamine neurotoxicity.
Clinical studies have shown the efficacy of pramipexole therapy in the late stages of Parkinson's disease, in which there has been a significant decrease in the number of motor disorders and a much later development of complications compared with levodopa monotherapy.
Pharmacokinetics
Absorption. Pramipexole after oral administration is rapidly and completely absorbed, reaching Cmax in plasma after about 1-3 hours. The absolute bioavailability of pramipexole exceeds 90%. The rate of absorption decreases with food intake, however, the total intake is not affected by food intake. Pramipexole is characterized by linear kinetics and a relatively small concentration variability between individual patients.
distribution. Vd is 400 liters. Plasma protein binding is less than 20%.
Metabolism and excretion. Slightly metabolized in the body. About 90% of the dose is excreted by the kidneys (80% - unchanged) and less than 2% - with feces. The total clearance of pramipexole is about 500 ml / min, renal clearance is about 400 ml / min.
The final T1 / 2 is 8 hours in young healthy volunteers and about 12 hours in older people.
Indications for treatment of the disease when the disease is weak or not associated with a combination of the following: or become unstable and fluctuations in the therapeutic effect occur (on-off).
Contraindications
hypersensitivity to pramipexole or any of the components of the drug
breastfeeding
age up to 18 years.
Precautions: renal failure, arterial hypotension, cardiovascular disease, simultaneous use with dopamine receptor agonists, sedatives, cimetidine, amantadine, ethanol pregnancy.
Composition
Active ingredient: pramipexole dihydrochloride monohydrate 1 mg
Excipients: mannitol MCC carboxymethyl starch sodium povidone K25 silicon dioxide colloidal magnesium sodium stearate stearyl fumarate
Dosage and administration
Inside, regardless of food intake, with plenty of fluids.
The daily dose should be evenly divided into 3 doses.
The initial daily dose of 264 micrograms of pramipexole base (375 micrograms of pramipexole dihydrochloride) should be increased every 5–7 days.
Side effects
From the nervous system: often - confusion, insomnia, dizziness, impaired consciousness, depression, anxiety infrequently - extrapyramidal syndrome, amnesia, hypesthesia, dystonia, myoclonus, tremor, ataxia, hypokinesia, delirium, suicidal mood rarely - malignant antipsychotic syndrome (hyperthermia, muscle rigidity, akathisia, autonomic lability, impaired thinking).
From the musculoskeletal system: rarely - muscle hypertonicity, leg muscle cramps, muscle twitching, arthritis, bursitis, myasthenia gravis, pain in the lumbosacral spine, chest pain, neck pain.
From the digestive system: often - loss of appetite, dysphagia, dyspepsia, abdominal pain, flatulence, diarrhea, dry mouth, vomiting.
From the respiratory system: infrequently - pharyngitis, sinusitis, rhinitis, dyspnea, increased cough, voice change is very rare - flu-like syndrome, pulmonary infiltration, pleural effusion.
From the genitourinary system: rarely - urinary tract infection, increased urination.
From the CCC side: often - orthostatic hypotension infrequently - tachycardia, increased CPK activity, angina pectoris, arrhythmias. In some patients, a decrease in blood pressure may occur at the beginning of treatment, especially if the dose is increased too quickly.
On the part of the sensory organs: often - conjunctivitis, accommodation paralysis, diplopia, cataracts, increased IOP, hearing loss.
Other: often - allergic reactions, fever, weight loss, sweating rarely - retroperitoneal fibrosis. Cases of development of peripheral edema were noted.
Drug interaction
Pramipexole binds to a small extent (less than 20%) with plasma proteins and undergoes biotransformation. Therefore, interactions with other drugs that affect plasma protein binding or excretion due to biotransformation are unlikely.
Selegiline and levodopa do not affect the pharmacokinetics of pramipexole. Pramipexole increases Cmax of levodopa by 40% and reduces Tmax from 2.5 to 0.5 hours.
Drugs that inhibit the active secretion of cationic drugs through the renal tubules (for example, cimetidine), or which themselves are eliminated by active secretion through the renal tubules, interact with pramipexole, which is expressed in a decrease in clearance of one or both drugs. In the case of the simultaneous use of amantadine and pramipexole, it is necessary to pay attention to such signs of dopamine excessive stimulation as dyskinesia, agitation or hallucinations. In such cases, it is necessary to reduce the dose.
Diltiazem, triamteren, verapamil, quinidine, quinine reduce the clearance of pramipexole by 20%.
Interaction with anticholinergic drugs and amantadine has not been studied. However, interaction with amantadine is possible, because drugs have a similar excretion mechanism. Anticholinergic drugs are mainly excreted by the metabolic route, so interaction with pramipexole is unlikely.
With an increase in the dose of pramipexole, a reduction in the dose of levodopa is recommended, while it is necessary to maintain the concentration of other antiparkinsonian drugs at a constant level.
Dopamine receptor agonists (derivatives of phenothiazine, butyrophenone, thioxanthene, metoclopramide) reduce the effectiveness of pramipexole.
Because of the possible cumulative effects, patients should be advised to be careful while using sedative drugs or ethanol (alcohol) and pramipexole, as well as taking medications that increase the concentration of pramipexole in the plasma (for example, cimetidine).
Overdose of
Symptoms: nausea, vomiting, hyperkinesia, hallucinations, agitation and decreased blood pressure.
Treatment: gastric lavage, symptomatic therapy. There is no specific antidote. The effectiveness of hemodialysis has not been established.
Storage conditions
In the dark place at a temperature of no higher than 25 ° C.
Term hodnosty
2 years
Deystvuyuschee substances
Pramypeksol
Pharmacy terms
Prescription
Form of Treatment
tablets
Pramipexole-Teva tablets 1 mg, 30 pcs. (Pramypeksol) newyork in pharmacy online. Cheap price, instruction, side effects, dosage. Pramipexole-Teva tablets 1 mg, 30 pcs. - Sale. PayPal accept. Free shipping newyork. Fast international shipping.
Submit your review to Earn 10 Reward Points click here to login
Write Your Own Review